Non-targeted metabolomics study and biomarker screening of prehypertensive liver-fire hyperactivity syndrome based on UPLC-Q-Exactive MS technology.
10.19540/j.cnki.cjcmm.20210323.201
- Author:
Yu WANG
1
;
Shu-Min LI
2
;
Chao LI
2
;
Wen-Qing YANG
2
;
Yun-Lun LI
3
Author Information
1. Affiliated Hospital of Shandong University of Traditional Chinese Medicine Ji'nan 250011, China.
2. Shandong University of Traditional Chinese Medicine Ji'nan 250355, China.
3. Affiliated Hospital of Shandong University of Traditional Chinese Medicine Ji'nan 250011, China Shandong University of Traditional Chinese Medicine Ji'nan 250355, China.
- Publication Type:Journal Article
- Keywords:
liver-fire hyperactivity syndrome(LFHS);
metabolomics;
prehypertension
- MeSH:
Biomarkers;
Chromatography, High Pressure Liquid;
Humans;
Liver;
Metabolomics;
Syndrome;
Technology
- From:
China Journal of Chinese Materia Medica
2021;46(11):2881-2888
- CountryChina
- Language:Chinese
-
Abstract:
In this study, patients with prehypertensive liver-fire hyperactivity syndrome(LFHS) were selected as the research objects. The plasma samples of healthy volunteers and patients with prehypertensive LFHS were analyzed by non-targeted metabolomics based on UPLC-Q-Exactive MS. The differential biomarkers and metabolic pathways were screened out by multivariate statistics and metabolic pathway analysis, which revealed the characteristics of metabolic patterns of the syndrome. Thirty-three potential biomarkers such as androsterone and lysophosphatidylcholine and 16 related metabolic pathways such as steroid hormone metabolism and lipid metabolism were identified, and a partial least squares-discriminant analysis(PLS-DA) model of traditional Chinese medicine(TCM) syndromes was preliminarily constructed: Y =-0.070X_(13)-0.006X_8+ 0.040X_5-0.152X_1+0.131X_(10)+0.036X_(11)+0.043X_(23)+0.076X_(16)+0.132X_(20)+0.081X_(19)-0.101X_(31)+0.082X_(15)-0.038X_9+0.079X_(24). The predictive value of the model was 88.1%, and the explanatory power was 88.4%. In this study, the characteristic metabolic pattern of the prehypertensive LFHS was distinguished and revealed by metabolomics. The constructed PLS-DA model is expected to provide an objective basis for the identification of TCM syndromes in prehypertension, and inspiration for exploring the biological basis of TCM syndromes at small-molecular and overall levels.
